May 15th 2024
Researchers say addressing socioeconomic differences may be the key to addressing this disparity.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
The future of actinic keratosis treatment
May 4th 2020It is estimated that 0.025% to 16% of all actinic keratosis (AK) lesions may progress into invasive SCC per year, and there is still no marker to predict which lesions will progress, according to a recent paper that outlined diagnostic challenges as well as current and pipeline treatment approaches.
A paradigm shift in squamous cell carcinoma treatment
March 30th 2020Recent advances in systemic therapies have led to the development of PD-1 checkpoint inhibitors, which one expert says may represent a paradigm shift in the treatment and management of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (SCC).
Genetic expression profiling for squamous cell carcinoma
October 18th 2019For many years, genetic expression profiling has helped physicians predict which patients are at the highest risk of having their melanoma metastasize. Now, this same approach could aid in treating squamous cell carcinoma of the skin.
Quality of life suffers in breast cancer patients with radiodermatitis
October 18th 2019Radiodermatitis affects approximately 95% of all patients who receive radiation therapy for cancer - many of who are women undergoing breast cancer treatment. A recent study has found that developing the condition has a significant and detrimental impact on breast cancer patients' overall quality-of-life.